Amgen Inc. (NASDAQ:AMGN) Shares Purchased by Sumitomo Mitsui Financial Group Inc.

Sumitomo Mitsui Financial Group Inc. boosted its holdings in Amgen Inc. (NASDAQ:AMGN) by 7.0% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 55,868 shares of the medical research company’s stock after buying an additional 3,634 shares during the period. Sumitomo Mitsui Financial Group Inc.’s holdings in Amgen were worth $14,561,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Wellington Management Group LLP increased its stake in Amgen by 2.1% during the third quarter. Wellington Management Group LLP now owns 239,354 shares of the medical research company’s stock worth $77,122,000 after acquiring an additional 4,942 shares during the last quarter. EP Wealth Advisors LLC increased its position in Amgen by 10.1% during the 3rd quarter. EP Wealth Advisors LLC now owns 32,852 shares of the medical research company’s stock worth $10,585,000 after purchasing an additional 3,024 shares in the last quarter. XTX Topco Ltd lifted its position in Amgen by 179.1% during the third quarter. XTX Topco Ltd now owns 5,902 shares of the medical research company’s stock valued at $1,902,000 after buying an additional 3,787 shares in the last quarter. Bontempo Ohly Capital Mgmt LLC grew its stake in Amgen by 5.2% during the third quarter. Bontempo Ohly Capital Mgmt LLC now owns 8,432 shares of the medical research company’s stock worth $2,717,000 after buying an additional 419 shares during the period. Finally, Dunhill Financial LLC increased its position in shares of Amgen by 5.1% in the third quarter. Dunhill Financial LLC now owns 1,098 shares of the medical research company’s stock worth $354,000 after acquiring an additional 53 shares in the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

Wall Street Analysts Forecast Growth

AMGN has been the subject of a number of research reports. StockNews.com raised shares of Amgen from a “buy” rating to a “strong-buy” rating in a research report on Saturday, March 29th. Bank of America increased their target price on Amgen from $275.00 to $294.00 and gave the company an “underperform” rating in a research note on Wednesday, March 5th. Royal Bank of Canada reissued an “outperform” rating and set a $324.00 price target on shares of Amgen in a research report on Friday, January 24th. Piper Sandler increased their price objective on shares of Amgen from $310.00 to $329.00 and gave the company an “overweight” rating in a research report on Monday, February 10th. Finally, UBS Group reissued a “hold” rating on shares of Amgen in a research report on Wednesday, February 12th. Two investment analysts have rated the stock with a sell rating, nine have assigned a hold rating, eleven have assigned a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, Amgen currently has an average rating of “Moderate Buy” and an average price target of $314.04.

Insider Buying and Selling

In related news, EVP Jonathan P. Graham sold 25,045 shares of the firm’s stock in a transaction that occurred on Friday, February 7th. The stock was sold at an average price of $293.12, for a total value of $7,341,190.40. Following the sale, the executive vice president now directly owns 28,987 shares in the company, valued at $8,496,669.44. This trade represents a 46.35 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Nancy A. Grygiel sold 1,589 shares of the business’s stock in a transaction on Wednesday, February 5th. The stock was sold at an average price of $304.47, for a total value of $483,802.83. Following the transaction, the senior vice president now owns 7,210 shares of the company’s stock, valued at $2,195,228.70. This trade represents a 18.06 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 69,341 shares of company stock worth $20,644,335 in the last three months. 0.69% of the stock is owned by insiders.

Amgen Stock Down 5.0 %

Shares of NASDAQ:AMGN opened at $294.39 on Monday. The company’s fifty day moving average is $304.18 and its two-hundred day moving average is $296.99. The company has a debt-to-equity ratio of 9.62, a quick ratio of 0.95 and a current ratio of 1.26. Amgen Inc. has a 1-year low of $253.30 and a 1-year high of $346.85. The stock has a market capitalization of $158.15 billion, a price-to-earnings ratio of 38.99, a price-to-earnings-growth ratio of 2.63 and a beta of 0.53.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Tuesday, February 4th. The medical research company reported $5.31 earnings per share for the quarter, topping the consensus estimate of $5.04 by $0.27. Amgen had a net margin of 12.24% and a return on equity of 176.32%. Equities analysts anticipate that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 6th. Investors of record on Friday, May 16th will be given a dividend of $2.38 per share. The ex-dividend date is Friday, May 16th. This represents a $9.52 dividend on an annualized basis and a yield of 3.23%. Amgen’s dividend payout ratio is currently 126.09%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.